FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a pharmaceutical composition for the treatment of PD-L1-mediated disease or condition, a method for producing a pharmaceutical composition, the use of a pharmaceutical composition in the manufacture of a drug for the treatment of PD-L1-mediated disease or condition, and a method for the treatment of PD-L1-mediated disease or condition. In one of embodiments, the pharmaceutical composition contains 30-80 mg/ml of an antibody to PD-L1 or its antigen-binding fragment, 5-50 mM of a succinate buffer, 30-90 mg/ml of saccharide, while saccharide is trehalose or sucrose, and 0.01-1.0 mg/ml of polysorbate 80, and the antibody to PD-L1 contains HCDR1, HCDR2 and HCDR3 that are represented under SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively, and LCDR1, LCDR2 and LCDR3 that are represented under SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
EFFECT: invention expands the arsenal of means for the treatment of PD-L1-mediated diseases or conditions.
16 cl, 3 dwg, 7 tbl, 6 ex
Title |
Year |
Author |
Number |
PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION |
2019 |
- Tyan, Chenmin
- Li, Khao
- Lyu, Syun
|
RU2791683C2 |
FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE |
2018 |
- Gu, Tszinmin
- Lo, Syao
- Tao, Vejkan
|
RU2776204C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE |
2018 |
- Fang Jingjing
- Yan Zhen
- Liu Xun
|
RU2779430C2 |
ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE |
2020 |
- Gu Xiaoling
- Ye Xin
- Ge Hu
- Tao Weikang
|
RU2807484C2 |
ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE |
2019 |
- Gu, Xiaoling
- Jiang, Jiahua
- Zhang, Lei
- Hu, Qiyue
- Gu, Jinming
- Tao, Weikang
|
RU2778085C2 |
ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF |
2020 |
- Yan, Yan
- Ge, Khu
- Tao, Vejkan
|
RU2822550C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE |
2018 |
- Tian, Chenmin
- Li, Hao
- Liu, Xun
|
RU2782792C2 |
USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS |
2017 |
- Sun, Sin
- Tsao, Gotsin
- Yan, Chanyun
- Chzhan, Lyanshan
- Go, Yun
|
RU2762746C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE |
2018 |
- Wu Tingting
- Li Hao
- Liu Xun
- Fu Yayuan
|
RU2771384C2 |
ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE |
2018 |
- Yan, Shude
- Jiang, Jiahua
- Hu, Qiyue
- Zhang, Lianshan
- Cao, Guoqing
- Qian, Xueming
- Teng, Fei
|
RU2779128C2 |